Treatment News : Drug Spurs Latently Infected Cells But Doesn’t Taper HIV Reservoir

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 25, 2014

Drug Spurs Latently Infected Cells But Doesn’t Taper HIV Reservoir

AIDS 2014Romidepsin, a cancer drug from the HDAC inhibitor class, awakened HIV-infected immune cells from their latent state, but it did not ultimately shrink the size of the viral reservoir in a small safety and efficacy trial, aidsmap reports. Ole Schmeltz Søgaard, MD, of Aarhus University Hospital in Denmark, presented findings from the Phase I/II clinical trial at the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia.

The trial gave three weekly injections of romidepsin to five men and one woman living with HIV. All of the participants were taking antiretrovirals (ARVs) and had an undetectable viral load at the study’s outset.

There were various indications that romidepsin was succeeding in reversing latency of HIV-infected cells and causing them to begin replicating virus again (this makes them susceptible to ARVs, which cannot combat dormant virus). The drug apparently increased histone H3 acetylation in immune cells, an effect that increased with each dose. This essentially means that the drug was indeed inhibiting enzymes that keep HIV tightly wound within an immune cell’s nucleus. Meanwhile, the levels of cell-associated HIV RNA in CD4s rose in all the participants; each successive dose led to a larger increase. The viral load in plasma also increased, to the level of detectability with a standard viral load test in five of the participants. The composition of CD4 and CD8 cells shifted so that there were more naive cells and fewer effector and central memory cells. Both types of immune cells exhibited reduced expression of a marker signaling cell exhaustion.

However, readings of the total HIV DNA found in the participants’ CD4 cells showed no significant change, suggesting that romidepsin apparently didn’t diminish the size of the viral reservoir.

The drug proved generally safe and well tolerated. The most common side effects were nausea, other gastrointestinal problems and fatigue.

In April 2013, news of Søgaard’s work on HDAC inhibitors led to a frenzy of inaccurate reporting in the popular press claiming that scientists were “within months” of a cure.

To read the aidsmap story, click here.

To read the conference abstract, click here.

Search: Romidepsin, HDAC inhibitor, aidsmap, Ole Schmeltz Søgaard, 20th International AIDS Conference, AIDS 2014, HIV, reservoir.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Is youth leadership important in the HIV/AIDS fight?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.